Joseph Ciaffoni's departure as Chief Executive Officer of Indivior Pharmaceuticals, Inc. was reported; the filing names no successor. As of November 4, 2026, Indivior Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 2, 2026, naming 1 departure (Form 8-K, November 2, 2026).
Sell to companies like Indivior Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Indivior Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-02. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Indivior Pharmaceuticals, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2025-10-30 (layoff filings and notices).
Also on the record for Indivior Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 30, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.4% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13D/A, by Oaktree Capital Holdings, LLC | 0.76% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Madison Avenue International LP | 3.5% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Fuller & Thaler Asset Management, Inc. | 3.72% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 6.55% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.35% of the class | 5%+ stakes | Source |
| March 23, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 3.8% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Fuller & Thaler Asset Management, Inc. | 5.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Madison Avenue International LP | 5% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by THE GOLDMAN SACHS GROUP, INC. | 2.9% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 14.3% of the class | 5%+ stakes | Source |
| December 30, 2025 | Stake report, Schedule 13D/A, by Oaktree Capital Holdings, LLC | 5.69% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Indivior Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Indivior Pharmaceuticals, Inc. and the records around it.
Indivior Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Layoff notices Oct 2025
- Who owns it
Companies that share a holder
- Oaktree Value Opportunities Fund, L.P. also filed stake reports on 4 other companies: TORM plc (Oct 2026), BRC Group Holdings, Inc. (May 2026)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
- Two Seas Capital LP also filed stake reports on 14 other companies: NEKTAR THERAPEUTICS (Sep 2026), Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026)
Watch Indivior Pharmaceuticals, Inc.
Get an email when Indivior Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Indivior Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Indivior Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Indivior Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 24 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-02 | Out | Chief Executive Officer | 8-K, 2026-11-02 |
Who leads Indivior Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Joseph Ciaffoni, departure reported (filed 2026-11-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Indivior Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Indivior Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Indivior Pharmaceuticals, Inc.Every change, in the filing's words
Departing: Joseph Ciaffoni, Chief Executive Officer
Effective Time, Joseph Ciaffoni ceased to serve as Chief Executive Officer of Indivior, Ryan Preblick ceased to serve as Chief Financial Officer of Indivior, Patrick Barry ceased to serve as Chief Commercial Officer of Indivior and Jeffrey Burris ceased to serve as Chief Legal Officer of Indivior.
- In addition, upon the date that Mr. Ciaffoni's employment terminates, all of Mr. Ciaffoni's RSU awards will accelerate and vest in full (including any RSU awards received with respect to previous PSU awards).
- Subject to the terms and conditions of the Barry Separation Agreement, Mr. Barry's outstanding RSUs and Converted Awards will be subject to the Separation Acceleration.
- Subject to the terms and conditions of the Burris Separation Agreement, Mr. Burris's outstanding RSUs and Converted Awards will be subject to the Separation Acceleration.
- Appointment of Officers Consistent with the terms of the Merger Agreement, the board of directors of Indivior (the "Board") approved the appointment, effective as of the Effective Time, of certain members of Supernus's pre-Merger management team as officers of the Combined Company, including Jack A. Khattar as Chief Executive Officer and Timothy C. Dec as Senior Vice President, Chief Financial Officer.
- In connection with the signing of the Merger Agreement, Supernus and Mr. Khattar entered into a Second Amended and Restated Employment Agreement, dated August 1, 2026 (the "Khattar Employment Agreement"), which became effective at the Effective Time.
Tools for this story
Each opens in a new tab, filled in for Indivior Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.